Neuropsychological and behavioral effects of postnatal dexamethasone in extremely low birth weight preterm children at early school age

Journal of Perinatology

Volumn 32, Issue 2, 2012, Pages 139-146

  Crotty, K C ^a   Ahronovich, M D ^a,b   Baron, I S ^a,b   Baker, R ^a,b   Erickson, K ^a   Litman, F R ^a,b  

^a INOVA FAIRFAX HOSPITAL FOR CHILDREN   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

bronchopulmonary dysplasia; chronic lung disease glucocorticoids; cognition; neurodevelopment

Indexed keywords

DEXAMETHASONE;

ARTICLE; CHILD; CHILD BEHAVIOR; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; EXECUTIVE FUNCTION; EXTREMELY LOW BIRTH WEIGHT; FEMALE; GESTATIONAL AGE; HUMAN; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; NEUROPSYCHOLOGY; OBSERVATIONAL STUDY; PARENTING EDUCATION; PERINATAL PERIOD; POSTNATAL CARE; PREMATURITY; RETROSPECTIVE STUDY; SCHOOL CHILD; SCORING SYSTEM; SEX DIFFERENCE; VISUAL MEMORY; VISUOMOTOR COORDINATION; WECHSLER INTELLIGENCE SCALE;

BIRTH WEIGHT; BRONCHOPULMONARY DYSPLASIA; CHILD; CHILD BEHAVIOR DISORDERS; COHORT STUDIES; DEVELOPMENTAL DISABILITIES; DEXAMETHASONE; EXECUTIVE FUNCTION; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, NEWBORN; MALE; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TESTS; POSTNATAL CARE; PREGNANCY; PREMATURE BIRTH; REFERENCE VALUES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SOCIOECONOMIC FACTORS; TERM BIRTH;

EID: 84856614998     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2011.62     Document Type: Article

References (43)

1. Kreider ML, Tate CA, Cousins MM, Oliver CA, Seidler FJ, Slotkin TA et al. Lasting effects of developmental dexamethasone treatment on neural cell number and size, synaptic activity, and cell signaling: critical periods of vulnerability, doseeffect relationships, regional targets, and sex selectivity. Neuropsychopharmacology 2006; 31(1): 12-35. (Pubitemid 43250938)
2. Brozanski BS, Jones JG, Gilmour CH, Balsan MJ, Vazquez RL, Israel BA et al. Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant. J Pediatr 1995; 126(5 Part 1): 769-776.
3. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics 2006; 117(1): 75-83. (Pubitemid 46050522)
4. Halliday HL. Clinical trials of postnatal corticosteroids: inhaled and systemic. Biol Neonate 1999; 76(Suppl 1): 29-40. (Pubitemid 29281294)
5. Halliday HL, Patterson CC, Halahakoon CW. A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide. Pediatrics 2001; 107(2): 232-240. (Pubitemid 32121235)
6. Raman L, Georgieff MK, Rao R. The role of chronic hypoxia in the development of neurocognitive abnormalities in preterm infants with bronchopulmonary dysplasia. Dev Sci 2006; 9(4): 359-367. (Pubitemid 43855815)
7. Thompson DK, Warfield SK, Carlin JB, Pavlovic M, Wang HX, Bear M et al. Perinatal risk factors altering regional brain structure in the preterm infant. Brain 2007; 130(Part 3): 667-677. (Pubitemid 46410727)
8. Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr 2001; 1: 1.
9. Doyle LW, Ehrenkranz RA, Halliday HL. Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010; 98(3): 217-224.
10. Grier DG, Halliday HL. Corticosteroids in the prevention and management of bronchopulmonary dysplasia. Semin Neonatol 2003; 8(1): 83-91. (Pubitemid 36356496)
11. Needelman H, Evans M, Roberts H, Sweney M, Bodensteiner JB. Effects of postnatal dexamethasone exposure on the developmental outcome of premature infants. J Child Neurol 2008; 23(4): 421-424. (Pubitemid 351460706)
12. Cummings JJ, D'Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med 1989; 320(23): 1505-1510. (Pubitemid 19145801)
13. Onland W, van Kaam AH, De Jaegere AP, Offringa M. Open-label glucocorticoids modulate dexamethasone trial results in preterm infants. Pediatrics 2010; 126(4): e954-e964.
14. Romagnoli C, Zecca E, Luciano R, Torrioli G, Tortorolo G. Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants: a 3-year follow-up. Pediatrics 2002; 109(6): e85.
15. Baud O. Is perinatal dexamethasone treatment safe in preterm infants? Dev Med Child Neurol Suppl 2001; 86: 23-25. (Pubitemid 32248941)
16. McEwen BS. Steroid hormones and brain development: some guidelines for understanding actions of pseudohormones and other toxic agents. Environ Health Perspect 1987; 74: 177-184. (Pubitemid 18061010)
17. Murphy BP, Inder TE, Huppi PS, Warfield S, Zientara GP, Kikinis R et al. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics 2001; 107(2): 217-221. (Pubitemid 32121232)
18. American-Academy-of-Pediatrics. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002; 109(2): 330-338.
19. Watterberg KL. Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010; 126(4): 800-808.
20. Hintz SR, Kendrick DE, Vohr BR, Poole WK, Higgins RD. Changes in neurodevelopmental outcomes at 18 to 22 months' corrected age among infants of less than 25 weeks' gestational age born in 1993-1999. Pediatrics 2005; 115(6): 1645-1651. (Pubitemid 43843175)
21. Short EJ, Klein NK, Lewis BA, Fulton S, Eisengart S, Kercsmar C et al. Cognitive and academic consequences of bronchopulmonary dysplasia and very low birth weight: 8-year-old outcomes. Pediatrics 2003; 112(5): e359.
22. Thompson DK, Wood SJ, Doyle LW, Warfield SK, Lodygensky GA, Anderson PJ et al. Neonate hippocampal volumes: prematurity, perinatal predictors, and 2-year outcome. Ann Neurol 2008; 63(5): 642-651.
23. Gross SJ, Anbar RD, Mettelman BB. Follow-up at 15 years of preterm infants from a controlled trial of moderately early dexamethasone for the prevention of chronic lung disease. Pediatrics 2005; 115: 681-687. (Pubitemid 43373029)
24. Jones R, Wincott E, Elbourne D, Grant A. Controlled trial of dexamethasone in neonatal chronic lung disease: a 3-year follow-up. Pediatrics 1995; 96(5 Part 1): 897-906.
25. O'Shea TM, Washburn LK, Nixon PA, Goldstein DJ. Follow-up of a randomized, placebo-controlled trial of dexamethasone to decrease the duration of ventilator dependency in very low birth weight infants: neurodevelopmental outcomes at 4 to 11 years of age. Pediatrics 2007; 120(3): 594-602. (Pubitemid 47358303)
26. Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004; 12: 363-373.
27. Elliott CD. Differential Ability Scales. The Psychological Corporation: San Anontio, TX, 1990.
28. Wechsler D. Wechsler Intelligence Scale for Children, 4th edn. The Psychological Corporation: San Antonio, TX, 2003.
29. Farrell Pagulayan K, Busch RM, Medina KL, Bartok JA, Krikorian R. Developmental normative data for the Corsi Block-tapping task. J Clin Exp Neuropsychol 2006; 28(6): 1043-1052. (Pubitemid 44034742)
30. Beery KE, Beery NA. The Beery-Buktenica Developmental Test of Visual-Motor Integration: Administration, Scoring, and Teaching Manual. Pearson Inc.: Minneapolis, MN, 2004.
31. Gardner RA, Broman M. The Purdue Pegboard: Normative data on 1334 school children. J Clin Child Psychol 1979; 1: 156-162.
32. Manly T, Robertson IH, Anderson V, Nimmo-Smith I. The Test of Everyday Attention for Children: Manual. Thames Valley Test Company Limited: Bury St Edmunds, 1999.
33. Wagner RK, Torgesen JK, Rashotte CA. Examiner's Manual: The Comprehensive Test of Phonological Processing. PRO-ED Inc.: Austin, TX, 1999.
34. Baron IS. Neuropsychological Evaluation of the Child. Oxford University Press: New York, 2004.
35. Gioia GA, Isquith PK, Guy SC, Kenworthy L. Behavior Rating Inventory of Executive Function. Psychological Assessment Resources Inc.: Odessa, FL, 2000.
36. Reynolds C, Kamphaus RW. Behavior Assessment System for Children-2. American Guidance Services Inc.: Circle Pines, MN, 1998.
37. Bhutta AT, Cleves MA, Casey PH, Cradock MM, Anand KJ. Cognitive and behavioral outcomes of school-aged children who were born preterm: a meta-analysis. JAMA 2002; 288(6): 728-737. (Pubitemid 34848226)
38. Baron IS, Ahronovich MD, Erickson K, Gidley Larson JC, Litman FR. Age-appropriate early school age neurobehavioral outcomes of extremely preterm birth without severe intraventricular hemorrhage: a single center experience. Early Hum Dev 2009; 85: 191-196.
39. Edgin JO, Inder TE, Anderson PJ, Hood KM, Clark CA, Woodward LJ. Executive functioning in preschool children born very preterm: relationship with early white matter pathology. J Int Neuropsychol Soc 2008; 14(1): 90-101.
40. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D,et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 2000; 83(3): F177-F181.
41. Halliday HL, Ehrenkranz RA, Doyle LW. Early (<8 days) postnatal corticosteroids forpreventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2010; (1) CD001146.
42. Halliday HL, Ehrenkranz RA, Doyle LW. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009; (1) CD001145.
43. Marlow N, Wolke D, Bracewell M, Samara M. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 2005; 325: 9-19. (Pubitemid 40075676)